NEONC TECHNOLOGIES HOLDINGS, INC.
NTHIDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How NTHI's past catalysts played out
NEO212 Oral Capsule
Diffuse Astrocytoma, IDH-Mutant
Perillyl alcohol
Glioblastoma Multiforme
NEO100
Residual, Progressive or Recurrent Grade II or III Meningioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NEO212 Oral Capsule | Phase 2 | Diffuse Astrocytoma, IDH-Mutant | - | - |
Perillyl alcohol | Phase 2 | Glioblastoma Multiforme | - | - |
NEO100 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NEONC TECHNOLOGIES HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in NEONC TECHNOLOGIES HOLDINGS, INC.'s (NTHI) pipeline across Phase 2. Its lead program is NEO212 Oral Capsule (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NEONC TECHNOLOGIES HOLDINGS, INC.'s next FDA catalyst?→
NEONC TECHNOLOGIES HOLDINGS, INC.'s (NTHI) next tracked catalyst is a Phase 2 expected December 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NTHI biotech catalysts?→
Add NTHI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NEONC TECHNOLOGIES HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.